Skip to main content

MJFF Publications

431 - 440 of 7665 Results
Title
Year
  • Year
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • RESTRICTED
    Title: Leucine-rich repeat kinase 2 at a glance
    Journal Name: Journal of Cell Science
    Publisher: The Company of Biologists
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1242/jcs.259724
    Citation Count: 3
  • RESTRICTED
    Title: No laughing white matter: Reduced integrity of the cortical cholinergic pathways in Parkinson's disease-related cognitive impairment
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2023.106243
    Citation Count: 6
  • RESTRICTED
    Title: Novel human pluripotent stem cell-derived hypothalamus organoids demonstrate cellular diversity
    Journal Name: iScience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.isci.2023.107525
    Citation Count: 2
  • RESTRICTED
    Title: Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment
    Journal Name: Patient Preference and Adherence
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.2147/ppa.s420051
    Citation Count: 0
  • RESTRICTED
    Title: Prediction of Parkinson’s disease pathogenic variants using hybrid Machine learning systems and radiomic features
    Journal Name: Physica Medica
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.ejmp.2023.102647
    Best OA location URL:
    Citation Count: 3
  • RESTRICTED
    Title: Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2023.2338
    Citation Count: 6
  • RESTRICTED
    Title: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105511
    Best OA location URL:
    Citation Count: 2
  • RESTRICTED
    Title: Spatially heterogeneous structure-function coupling in haemodynamic and electromagnetic brain networks
    Journal Name: NeuroImage
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuroimage.2023.120276
    Citation Count: 2
  • RESTRICTED
    Title: Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-023-00573-2
    Citation Count: 2
  • RESTRICTED
    Title: NeuroBridge: a prototype platform for discovery of the long-tail neuroimaging data
    Journal Name: Frontiers in Neuroinformatics
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fninf.2023.1215261
    Citation Count: 1
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.